World News

Liminatus went public in 2022 through a SPAC merger and initially highlighted several immune-modulating therapies originating from research collaborations in the United States and South Korea.

If approved, MAVIRET would become one of the few therapies in the European Union indicated for both acute and chronic HCV infection.

Through the new framework, WHO and AMA will coordinate efforts to streamline approval processes, enhance post-market surveillance, and build regulatory workforce capacity.

Wegovy® 7.2 mg is already available in the European Union for adults with obesity through three separate 2.4 mg injections administered weekly.

Once completed, the acquisition will integrate SPR’s technology into Medtronic’s broader pain management strategy, allowing the company to offer additional options for patients and clinicians seeking alternatives to drug-based therapies.

Health authorities have continued to emphasise coordinated cross-border surveillance, especially given the movement of populations between affected regions in DRC and Uganda.

The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.

CVC, already the majority shareholder with a 46.8% stake, has positioned the move as a long-term strategic consolidation rather than a short-term financial transaction.

Since December 2025, CBC Group, together with the company’s directors have cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).

The partnership builds on Africa CDC’s recent efforts to accelerate the deployment of community health workers across the continent through collaborations with regional partners.